AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, ...
Immunotherapy innovation is saving the lives of cancer patients across the country, while researchers continue to break new ground in this growing oncology field. When Sameek Roychowdhury, MD, PhD, ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
MedPage Today on MSN
Immuno-oncology tops embolization for intermediate-grade liver cancer
Time to failure improved by 5 months, but questions raised about endpoint, applicability t ...
Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...
In the third quarter of 2025, Mirador closed a $250 million Series B financing, bringing total capital raised to more than $650 million since the company launched in March 2024. The proceeds enable ...
If you’ve ever conducted experiments with compounds targeting tumor cells, you likely understand the disappointment of promising results in cell cultures not translating to success in live animal ...
Immunotherapy is proving a massive draw for investors and big pharma companies alike. These privately-owned immuno-oncology startups have bagged hefty funding rounds in the last two years. For decades ...
A sensor identifies misfolded protein biomarkers in the blood. This offers a chance to detect Alzheimer's disease before any symptoms occur. Researchers intend to bring it to market maturity. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback